NCT06751433 Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic Scars
| NCT ID | NCT06751433 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Herbarium Laboratorio Botanico Ltda |
| Condition | Acceptability Study |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-04-03 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 80 participants in total. It began in 2025-04-03 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluation of the safety and topical efficacy of a scar gel after 90 days of continuous use, comparing it to a benchmark for preventing hypertrophic scars and improving appearance, hydration and pigmentation.
Eligibility Criteria
Inclusion Criteria: 1. Participants of both sexes aged between 18 and 70 years; 2. Participants with recent scars (\<30 days); 3. Participants with phototypes III to VI according to the Fitzpatrick scale; 4. Agree to follow the trial procedures and attend the center on the days and times determined for evaluations; 5. Understand, agree to and sign the free and informed consent form. 6. Types of scars: cesarean section, breast implant or blunt cut injury. Exclusion Criteria: 1. Pregnancy or risk of pregnancy; 2. History of atopic or allergic reactions to cosmetic products; 3. Participants who are using topical antibiotics or other skin products on the same area being evaluated; 4. Immunosuppression due to drugs or active diseases; 5. Decompensated endocrine diseases; 6. Relevant clinical history or current evidence of alcohol or other drug abuse; 7. Known history or suspected intolerance to products in the same category; 8. Intense sun exposure up to 15 days before the evaluation; 9. Patients who are using topical antibiotics or other skin products on the same area being evaluated.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06751433 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Acceptability Study. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06751433 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06751433 currently recruiting?
Yes, NCT06751433 is actively recruiting participants. Contact the research team at contato@medcinpesquisa.com.br for enrollment information.
Where is the NCT06751433 trial being conducted?
This trial is being conducted at Osasco, Brazil, Osasco, Brazil.
Who is sponsoring the NCT06751433 clinical trial?
NCT06751433 is sponsored by Herbarium Laboratorio Botanico Ltda. The trial plans to enroll 80 participants.